UNSPSC 51313108: Buclizine

This classification denotes a histamine-1 receptor antagonist with the molecular formula C28H33ClN2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0C94V6X681, chemically known as piperazine, 1-(p-tert-butylbenzyl)-4-(p-chloro-.alpha.-phenylbenzyl)-, dihydrochloride but generally known as buclizine, which bears US NIH Compound Identifier 6729. Buclizine most often comes in base, dihydrochloride, and hydrochloride forms.

UNSPSC 51313108 Buclizine is a Commodity code whose recent state and local procurement activity centers on pharmaceutical and over-the-counter product procurement rather than buclizine specifically. The code shows three major recent solicitations across health and human services agencies: Seminole County, Florida seeking Naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission issuing a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, soliciting generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities. The scope spans pharmaceutical distribution logistics, supply-chain compliance (including FDA requirements and Drug Supply Chain Security Act certification), pricing models, and inventory management for community health initiatives and state pharmacy benefit programs. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing vehicles serving multiple jurisdictions.

The three recent opportunities span Florida, Texas, and Minnesota with multi-state reach through the MMCAP cooperative. Seminole County's IFB 60459723LAS, posted June 30, 2026 with response due July 26, 2023, seeks 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with one-year renewal option and requires E-Verify compliance and standard insurance coverage. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, explores vendor capabilities for direct-to-manufacturer prescription contracting outside traditional pharmacy benefit manager and wholesaler channels, functioning as market intelligence before a formal RFP. MMCAP's RFP S1070000015802, posted January 20, 2026 with proposals due March 26, 2026, establishes multi-award contracts for generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with products effective July 1, 2026; awards are weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and fee agreement.